Drugs / VT-5006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07310264 | Oct 2025 → Sep 2026 overdue | Parkinson disease | Vertero Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VT-5006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07310264 ↗ |
| Route | Oral | “orally administered VT-5006” NCT07310264 ↗ |